Welcome to our dedicated page for Alkermes news (Ticker: ALKS), a resource for investors and traders seeking the latest updates and insights on Alkermes stock.
Alkermes plc develops and commercializes neuroscience medicines, with proprietary commercial products used in alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Company news commonly covers quarterly financial results, full-year expectations, commercial execution and presentations at healthcare and CNS investor conferences.
Clinical and medical updates focus on the company’s sleep-wake and psychiatric portfolio, including LYBALVI in schizophrenia and bipolar I disorder and alixorexton, an investigational oral selective orexin 2 receptor agonist in development for narcolepsy and idiopathic hypersomnia. Other updates include peer-reviewed data publications, research award programs and corporate developments tied to Alkermes’ biopharmaceutical operations.
Alkermes (Nasdaq: ALKS) responded on November 14, 2025 to Avadel's announcement about a possible Lundbeck offer for Avadel. Alkermes said its board is considering options with advisors and reiterated contractual protections in the existing Transaction Agreement.
Key contractual points: Avadel cannot terminate the agreement to accept a Company Superior Proposal unless its board, in good faith, determines doing so meets fiduciary duties and Avadel gives Alkermes at least five (5) Business Days written notice and engages in good‑faith discussions about amendments. Avadel also cannot change its board recommendation or sign with Lundbeck until those steps occur. Alkermes said a further announcement will follow as appropriate and will post this release on its website by 12:00 p.m. ET on November 17, 2025.
Alkermes (Nasdaq: ALKS) announced positive topline results from the Vibrance-2 phase 2 study of once-daily alixorexton in patients with narcolepsy type 2 on Nov. 12, 2025. In a randomized, double-blind trial (n=93) alixorexton met dual primary endpoints at week eight: clinically meaningful improvements in wakefulness (MWT) and excessive daytime sleepiness (ESS) versus placebo.
By pre-specified analysis, the 14 mg and 18 mg doses achieved statistical significance on MWT, and the 18 mg dose achieved statistical significance on ESS. Alixorexton was generally well tolerated; most TEAEs were mild-to-moderate and no serious TEAEs were reported. Alkermes plans to start a global phase 3 program in Q1 2026.
Alkermes (Nasdaq: ALKS) said management will participate in two investor conferences in November 2025: the Stifel 2025 Healthcare Conference on Nov. 13, 2025 at 2:40 p.m. ET and the Jefferies Global Healthcare Conference in London on Nov. 19, 2025 at 11:30 a.m. ET.
Both events will be webcast live and the webcasts will be available under the Investors tab at www.alkermes.com and archived for 14 days.
Alkermes (Nasdaq: ALKS) filed an Opening Position Disclosure (Form 8.1(a)&(b)) under Irish Takeover Panel rules on 5 November 2025 with a position date of 3 November 2025. The form names Avadel Pharmaceuticals plc as the related offeror/offeree and states Alkermes as the offeror. The disclosure reports no indemnities, option arrangements, or derivative agreements and no supplemental Form 8 attached. It lists J.P. Morgan staff holdings totalling 13,553 ordinary shares (0.0139%) in Avadel, split between two entities (53 and 13,500 shares).
Alkermes (Nasdaq: ALKS) reported Q3 2025 total revenues of $394.2 million and GAAP net income of $82.8 million (diluted EPS $0.49) for the quarter ended Sept. 30, 2025. Total proprietary net sales were $317.4 million, led by VIVITROL $121.1M, ARISTADA i $98.1M and LYBALVI $98.2M (LYBALVI +32% revenue, +25% prescriptions vs Q3 2024).
The company recorded cash and investments of $1.14 billion and raised its 2025 outlook: total revenues to $1.43–$1.49B, GAAP net income to $230–$250M, EBITDA to $270–$290M and adjusted EBITDA to $365–$385M. R&D expense for the quarter was $81.7M.
Alkermes (Nasdaq: ALKS) agreed to acquire Avadel (Nasdaq: AVDL) for $18.50 per share in cash plus a non-transferable CVR of $1.50 per share contingent on FDA approval for idiopathic hypersomnia, valuing the deal at up to $20.00 per share and ≈$2.1 billion. The boards approved the transaction, which is expected to close in Q1 2026 subject to regulatory and shareholder approvals.
The acquisition adds FDA-approved LUMRYZ (once-at-bedtime sodium oxybate) with expected 2025 net revenues of $265–$275 million, ~3,100 patients on therapy as of June 30, 2025, and a U.S. oxybate-eligible population >50,000. Alkermes expects the deal to be immediately accretive and will finance with cash on hand plus new debt, with J.P. Morgan providing committed financing.
Alkermes (Nasdaq: ALKS) will report third quarter 2025 financial results and host a conference call and webcast on Oct 28, 2025 at 8:00 a.m. ET (12:00 p.m. GMT). The event will include slides available on the company's Investors website and a replay posted about two hours after the event.
Live access: U.S. dial +1 877 407 2988; international dial +1 201 389 0923. Alkermes is a global biopharmaceutical company focused on neuroscience with marketed products for alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline including narcolepsy and idiopathic hypersomnia. Headquarters in Ireland with R&D in Massachusetts and manufacturing in Ohio.
Alkermes (Nasdaq: ALKS) has appointed Joshua Reed as Chief Financial Officer, effective September 15, 2025. Reed brings over 30 years of financial leadership experience in biotechnology and pharmaceutical sectors, most recently serving as CFO of Omega Therapeutics.
Reed's extensive background includes CFO roles at Aldeyra Therapeutics and leadership positions at Bristol Myers Squibb, where he served as Vice President and Head of Finance Operations for the U.S. and Puerto Rico. He currently serves on the board of Scholar Rock Holding Corporation and holds degrees from Rutgers University and the University of Michigan's Ross School of Business.
Alkermes (Nasdaq: ALKS) announced the launch of its 8th Annual Pathways Research Awards program, offering grants of up to $100,000 per project to early-career investigators in neuroscience. The program will accept applications from September 15 through December 15, 2025.
This year's program expands its focus to include research on sleep and circadian disturbances associated with bipolar I disorder and schizophrenia. Since its inception in 2018, the program has provided $2.7 million in funding to 27 researchers across the United States. Eligible applicants must be M.D.s, Ph.D.s, or equivalent, within five years of initial academic appointment or current post-doctoral fellows at U.S. institutions.
Alkermes (Nasdaq: ALKS) announced positive results from the Vibrance-1 phase 2 study of alixorexton in narcolepsy type 1 (NT1) patients at World Sleep Congress 2025. The study demonstrated clinically meaningful and statistically significant improvements in wakefulness, cognition, and fatigue across all tested doses (4mg, 6mg, and 8mg).
Key findings include: All dose groups achieved normative wakefulness with mean sleep latency of 24-28 minutes, significant improvements in the Epworth Sleepiness Scale, and over 40% of patients at higher doses achieved complete cataplexy reduction. The drug was generally well-tolerated with no serious adverse events reported.
Based on these results, Alkermes plans to initiate a global phase 3 program in Q1 2026. Additional phase 2 studies (Vibrance-2 and Vibrance-3) are ongoing for narcolepsy type 2 and idiopathic hypersomnia.